A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression

Trial Profile

A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Ceritinib (Primary) ; Everolimus
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jun 2016 Planned primary completion date changed from 1 Apr 2023 to 1 Jun 2023.
    • 22 Jun 2016 Status changed from not yet recruiting to recruiting.
    • 08 Feb 2016 Planned primary completion date changed from 1 Dec 2022 to 1 Apr 2023 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top